Project Scope The goals of this project is to obtain broad industry and CRO feedback on the current publicly available OCE/OOD standard safety data request (found at: https://www.fda.gov/media/133252/download) and assist with the development of resources to assist Sponsors with implementation of these data specifications. There is tremendous variability and inconsistency in the use of the CDISC ADaM data standard in safety datasets for oncology NDA/BLA applications submitted to FDA. This variability leads to inefficiency in review for the FDA and multiple information requests to applicants during the course of the review to resolve inconsistencies in analyses between FDA and applicants. The Oncology Centre of Excellence (OCE)/Office of Oncologic Diseases (OOD) has developed a pilot standard safety data request for datasets submitted with NDA/BLA applications and instructions for conducting select safety analyses to create a common set of data elements with common use of these variables for safety analyses. The Stakeholders include FDA reviewers and analysts, industry, CROs, and software developers. |
CURRENT STATUS Q22021 |
Phase 1 was completed as scheduled but an additional phase to review the incorporation of comments has been introduced, thereby delaying the initiation of Phase 2. The project is currently on hold pending the publication of v1.4, which is taking longer than initially expected due to competing priorities for those at the FDA who are developing the specifications. |
Project Leads | |
Abhilasha Nair | abhilasha.nair@fda.hhs.gov |
Chris Price | chris.price@phuse.global |
Peter Schotland | |
Paula Rowley (PHUSE Project Assistant) | paula@phuse.global |
Deliverables | Timelines |
Feedback on publicly available OCE/OOD safety data request. | Q22021 |
Development of basic resources for sponsors to assist implementation (e.g. CRF design to collect relevant data and linkages for adverse events and dataset preparation for laboratory analyses or other resources requested or found to be needed during the feedback process). | Q22021 |
Project Members | Organisation |
Abhinav Srivastva | Exelixis |
Bhupendra Mistry | Roche |
Cathy Bezek | Astellas |
Cindy Marabotti | Sanofi |
Diane Wold | CDISC |
Gopi Vegesna | Astellas |
Greg Ball | Merck |
Gregory Purnsley | Pfizer |
Hitesh Thacker | Labcorp |
Hong Qi | Merck |
Joy Ge | Merck |
Karen Ying | GSK |
Ken Maahs | Janssen Research & Development |
Kim Musgrave | Amgen |
Lihui Deng | Bristol Myers Squibb |
Lindsay McLean | PHASTAR |
Marleen Nijs | Janssen Research & Development |
Project Members | Organisation |
Matt Smith | Pfizer |
Maxime Rouch | Sanofi |
Paul Frost | GEM Programming |
Pavan Kumar | GSK |
Peter Bonata Bayer | Bayer |
Sasabindu Tripathy | Takeda |
Srinivas Kolamuri | Novartis |
Suriaya Walsh | AstraZeneca |
Suwen Li | Roche |
Tatiana Sotingco | Janssen Research & Development |
Tim Young | GSK |
Venkata Rajesh Datla | Genmab |
Vishnu Dabbiru | GSK |
Wenyun Ji | AbbVie |
Whitney Boeckel | GSK |
William Palo | AbbVie |